Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

▤ Summary

Rani Therapeutics announced an oversubscribed private placement expected to bring in about $60.3 million before expenses. The company also disclosed a $6 million debt conversion tied to the financing. Management said the combined capital should fund operations into 2028 and support continued development of the RaniPill platform. The deal includes new and existing biotech investors and gives two investors board designation rights at closing. Rani plans to use the proceeds to advance its oral delivery technology and pipeline.

$ Funding

▦ Linked Companies